Top news of the week: 04.10.2023.
Regeneron's lymphoma drug odronextamab gets FDA priority review
Regeneron's lymphoma drug odronextamab gets FDA priority review
Point Biopharma Global’s stock jumps more than 80% after Lilly merger deal
Point Biopharma Global, Inc.’s stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. said it will pay $12.50 a share to acquire the...
Hospital Authority to expand clinical database access for R&D
It is launching a data collaboration lab with Hong Kong Science and Technology Parks.
Lexeo’s $100 Million IPO: Jab in the Arm for Biotech?
October 3, 2023 It's been nothing but crickets in the biotech initial public offering (IPO) space this year, but investors who are hungry for a new pharma
The US Stock Market Could Crack in October: 6 'Strong Buy' European Dividend Aristocrats to Buy Now
Here are six European Dividend Aristocrats that are the most liquid and well-known for U.S. investors who are looking for income and a degree of diversification away from the American ...
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.1x Aytu BioPharma, Inc. ( NASDAQ:AYTU ) is definitely a...
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.29%
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.29%